On October 17, 2022 Immunovia AB (Nasdaq: IMMNOV) (Stockholm: IMMNOV) reported that it enters into a strategic partnership with Proteomedix to leverage its substantial joint development experience in diagnostic technologies for the detection of cancer (Press release, Immunovia, OCT 17, 2022, View Source [SID1234622088]). This will enable increased R&D productivity for Immunovia as the Company continues to strengthen its commercial development in the US.  

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The partnership between Immunovia and Proteomedix leverages the companies’ complementary R&D capabilities and advances their R&D efforts. With this partnership, Immunovia will gain a more flexible R&D organization, increase its R&D productivity, and will focus internal resources on the commercial build up, thus further accelerating the roll-out of IMMray PanCan-d.  The partnership capitalizes on the combined expertise of two leading innovators in proteomics-based diagnostics, who have both launched innovative oncology tests, Immunovia with IMMray PanCan-d in the U.S. and Proteomedix with Proclarix in Europe.

Proteomedix, a Swiss-based Company, was founded 2010 as a spin-off company of ETH Zurich to bring together the expertise of a multi-disciplinary group of world-leading scientists and clinicians in proteomic-based diagnostics. The Company is focused on research and development that relies on a network of clinicians, IVD experts, laboratories, and marketers. Proteomedix has developed a blood-based prostate cancer test using proteomics technology that measures cancer-associated proteins, using highly reproducible immunoassays. 

"We are very excited to enter this partnership with Immunovia, an early-commercial company like us with an innovative diagnostic test in oncology. This partnership enables both companies to faster take critical steps forward by leveraging our combined expertise to increase R&D efficiency. For Proteomedix, this partnership demonstrates how our biomarker assay development expertise can be deployed beyond prostate cancer," said Helge Lubenow – CEO, Proteomedix.

"Immunovia is entering a new phase with an increased focus on the commercialization of our IMMray PanCan-d test in the US while maximizing our R&D productivity. This partnership with Proteomedix will combine leading proteomics-based researchers with state-of-the art capabilities from both companies to create an outstanding R&D platform," said Philipp Mathieu – CEO and President, Immunovia.

In connection with the new R&D partnership, Linda Dexlin Mellby, Vice President Research & Development at Immunovia, will be leaving the company as of 4 November.

"Linda has been instrumental in the development of Immunovia’s IMMray PanCan-d test over the past nine years. We thank her for her many contributions to the company and wish her all the best in her future endeavors," continued Philipp Mathieu – CEO and President, Immunovia. 

On October 17, 2022 ImaginAb, Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT) products, reported the completion of a Master Services Agreement with Cyclotek, a leading radiopharmaceutical manufacturer in Australia and New Zealand, for the commercial manufacturing and distribution of its investigational CD8 ImmunoPET agent in Australia (Press release, ImaginAb, OCT 17, 2022, View Source [SID1234622086]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Cyclotek will initially supply patient-specific unit doses of the imaging agent from its Melbourne-based radiopharmacy to clinical sites across Australia, for ImaginAb’s clinical trials and the clinical sites for immunotherapy studies sponsored by pharma and biotech companies that have licensed CD8 ImmunoPET.

Ian Wilson, Chief Executive Officer of ImaginAb, said:

"ImaginAb is very pleased to be partnering with Cyclotek, a well-established and reliable supplier of quality PET radiopharmaceuticals in Australia as we continue to strengthen and expand our CD8 ImmunoPET manufacture network in Australia and across the globe. This agreement is part of our continued thrust to establish a worldwide leading manufacturing distribution network for our imaging agent, as we progress towards our goal to gain regulatory approval of our technology in multiple geographies."

Greg Santamaria, Chief Executive Officer of Cyclotek, added:

"Cyclotek is delighted to be working with ImaginAb to supply its investigational CD8 ImmunoPET imaging agent as we continue to expand and develop our operational capacity for the benefit of patients across Australia and New Zealand."

On October 17, 2022 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported that management will host a live webcast and conference call in conjunction with its data presentations at the 34th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium in Barcelona, Spain on Friday, October 28, 2022 at 8:30 a.m. EDT (Press release, Nuvalent, OCT 17, 2022, https://www.prnewswire.com/news-releases/nuvalent-to-host-conference-call-to-discuss-preliminary-phase-1-data-from-arros-1-clinical-trial-of-nvl-520-and-additional-preclinical-updates-in-conjunction-with-34th-eortc-nci-aacr-symposium-301650281.html [SID1234622085]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will be accessible through the "Events" section of the Investors page of www.nuvalent.com or by dialing (866) 652-5200 (domestic) or (412) 317-6060 (international) and referring to conference ID 10171503. A replay and accompanying slides will be archived on the Nuvalent website for 30 days.

On October 17, 2022 PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, reported that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology drug candidates, at SITC (Free SITC Whitepaper) (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)) Annual Meeting taking place November 8-12 in Boston (Press release, PharmAbcine, OCT 17, 2022, View Source [SID1234622084]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 7, the abstract of the presentation will be made available on SITC (Free SITC Whitepaper) website.The full poster can be accessed at Poster Hall between 9:00 a.m. and 9:00 p.m. ET on November 10.

About PMC-309
PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, an immune checkpoint receptor mainly expressed on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells), it can play a pivotal role in maintaining the immunosuppressive environment around the tumor cells. In the nonclinical studies, it has been discovered that PMC-309 can promote both innate immunity (monocyte activation, M1 macrophage proliferation) and adaptive immunity (T cell activation) unlike the existing drugs which show significant changes only in adaptive immunity. In addition, the in vivo data showed that PMC-309 demonstrated significantly improved tumor growth inhibition when used in combination with an anti-PD-1 drug compared to both monotherapies of PMC-309 and an anti-PD-1 drug. These findings suggest that PMC-309 can offer a new treatment strategy in immuno-oncology area as it can be used in combination with other drugs to improve their low-response rates. The GLP-Toxicology studies are already completed, and no serious safety issues were observed. The Company plans to submit Clinical Trial Application in late 2022.

On October 17, 2022 Exacis Biotherapeutics Inc. ("Exacis" or the "Company"), a development-stage immuno-oncology company working to harness the immune system to cure cancer, reported that it has signed an option agreement with Eterna Therapeutics Inc. ("Eterna") providing Eterna the right to license up to four off-the-shelf, iPSC derived NK cell and T cell cancer treatments to be produced using Exacis’ proprietary mRNA-reprogrammed iPSCs that will be engineered with Exacis’ mRNA-based gene editing platform (Press release, Exacis Biotherapeutics, OCT 17, 2022, View Source [SID1234622083]). The option agreement provides Exacis and Eterna until December 31, 2022 to negotiate the license agreement. Terms include an upfront license fee, development and commercialization milestones, and single-digit royalties.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Exacis’ non-viral platform uses mRNA-reprogrammed iPSCs engineered for stealthing and performance using Exacis’ proprietary mRNA-based gene editing system including mRNA vector RiboSlice and nuclease NoveSlice. The Exacis process avoids use of potentially harmful DNA and viruses by using mRNA.

Dr. Dimitri Goundis, Exacis’ Chief Business Officer commented, "Exacis is committed to using its powerful platform to produce safe and effective immune cell therapies for cancer. Eterna is well positioned to rapidly advance products toward the clinic and patients".

Dr. Matt Angel, Eterna’s Interim Chief Executive Officer added, "The opportunity to partner with Exacis and add next-generation mRNA-based NK and T cell therapies to our oncology portfolio is an important step in advancing Eterna’s mission to realize the potential of cell engineering to provide patients with transformational new medicines."